Teclistamab in Relapsed or Refractory Multiple Myeloma

To the Editor: Moreau and colleagues (August 11 issue) 1 found that, in patients with relapsed or refractory myeloma, treatment with teclistamab, a T-cell–redirecting bispecific antibody that targets CD3 on T cells and B-cell maturation antigen (BCMA) expressed on myeloma cells, resulted in a high overall response of 63.0% and a median progression-free survival of 11.3 months (95% confidence interval, 8.8 to 17.1). In addition, they found a correlation between the percent change from baseline in serum levels of soluble BCMA and response. However, we would appreciate the authors clarifying whether high levels of soluble BCMA at baseline were associated with . . .